Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer [ChIP-seq]

ABSTRACT: AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer [ChIP-seq]

PROVIDER: PRJNA648907 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12329926.fastq.gz	Fastqsanger.gz
	SRR12329927.fastq.gz	Fastqsanger.gz
	SRR12329928.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer [ChIP-seq]

Project description:Abstract:AP-2α (encoded by TFAP2A) functions as a tumor suppressor and influences response to therapy in several cancer types. We aimed to characterize regulation of the transcriptome by AP-2α in colon cancer. Results: Knockout of TFAP2A induced significant alterations in the transcriptome including repression of TGM2, identified as a primary gene target of AP-2α. Loss of AP-2α delayed progression through S-phase into G2/M and decreased phosphorylation of AKT, effects that were mediated through regulation of TGM2. Buparlisib (BKM120) repressed in vitro invasiveness of HCT116 and LS-180; however, loss of AP-2α induced resistance to Buparlisib. Similarly, Buparlisib repressed PHH3 and growth of tumor xenografts and increased overall survival of tumor-bearing mice, whereas, loss of AP-2α induced resistance to the effect of PI3K inhibition. Conclusion: Loss of AP-2α in colon cancer leads to prolonged S-phase through altered activation of AKT leading to resistance to the PI3K inhibitor, Buparlisib. The findings demonstrate an important role for AP-2α in regulating progression through the cell cycle and indicates that AP-2α is a marker for response to PI3K inhibitors.

2021-06-01 | GSE155165 | GEO

AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer [RNA-seq]

2021-06-01 | GSE155162 | GEO

AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer

Project description:AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer

| PRJNA648910 | ENA

AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer [RNA-seq]

Project description:AP-2α Regulates S-phase and is a Marker for Sensitivity to PI3K-inhibitor Buparlisib in Colon Cancer [RNA-seq]

| PRJNA648876 | ENA

Genome-wide identification of AP-2α targets in bladder cells by RNA-seq (Control vs AP-2α OE)

Project description:TFAP2A (AP-2α) is a member of the transcription factor AP-2 family, functions as a tumor suppressor by regulating the expression of various cancer-related genes; its expression is positively correlated with chemosensitivity and survival of cancer patients.

2020-12-08 | GSE128715 | GEO

Genome-wide identification of AP-2α targets in bladder cells by RNA-seq (Control vs AP-2α KD)

2020-12-08 | GSE128714 | GEO

AP-2α pull down from E12.5 cortex

Project description:Identificatin of interaction partners of AP-2α via pull down from the cortex of E12.5 mice followed by quantitative mass spectrometry.

2023-12-11 | PXD047202 | Pride

Genome-wide identification of AP-2α by ChIP-chip in breast cancer cell line MCF7

Project description:The AP-2 family of transcription factors is involved in the regulation of embryonic development, cell proliferation and tumorigenesis. To date, five members of the AP-2 family have been identified: AP-2α, AP-2β, AP-2γ, AP-2δ and AP-2ε. All AP-2 proteins bind as homo- or heterodimers to the consensus sequence of 5'- GCCNNNGGC-3' and directly regulate transcription of their target genes. Among these, AP-2α is the best-characterized gene.

2020-12-08 | GSE128589 | GEO

Genome-wide identification of AP-2α targets in bladder cells by RNA-seq (Control vs AP-2α KD)

Project description:Genome-wide identification of AP-2α targets in bladder cells by RNA-seq (Control vs AP-2α KD)

| PRJNA528627 | ENA

Genome-wide identification of AP-2α targets in bladder cells by RNA-seq (Control vs AP-2α OE)

Project description:Genome-wide identification of AP-2α targets in bladder cells by RNA-seq (Control vs AP-2α OE)

| PRJNA528626 | ENA